# A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)

> **NCT04659031** · PHASE1 · COMPLETED · sponsor: **Abcuro, Inc.** · enrollment: 19 (actual)

## Conditions studied

- Inclusion Body Myositis

## Interventions

- **DRUG:** ABC008

## Key facts

- **NCT ID:** NCT04659031
- **Lead sponsor:** Abcuro, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-25
- **Primary completion:** 2025-01-10
- **Final completion:** 2025-01-10
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2025-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04659031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04659031, "A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04659031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*